Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?

AstraZeneca shares fell more than 6% in early trading on Monday after reports emerged that the British pharmaceutical giant had held preliminary discussions with US-based Bristol Myers Squibb over a p...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。